March 18, 2021Open Access

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Our analysis failed to support application of TMB-H as a biomarker for treatment with ICB in all solid cancer types. Further tumor type-specific studies are warranted.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

McGrail et al. (Thu,) studied this question.

synapsesocial.com/papers/69da5f6294a959ed41a3c743 https://doi.org/https://doi.org/10.1016/j.annonc.2021.02.006

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

121-Gene Recurrence Score Assay and Outcomes of Adjuvant Radiotherapy in Elderly Women With Early-Stage Breast Cancer After Breast-Conserving Surgery2019 · 360 citations
2Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies2011 · 506 citations
3Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy2018 · 2,356 citations
4Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma2019 · 1,110 citations
5Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade2016 · 3,112 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo